495 related articles for article (PubMed ID: 28593446)
41. C3 glomerulopathy - understanding a rare complement-driven renal disease.
Smith RJH; Appel GB; Blom AM; Cook HT; D'Agati VD; Fakhouri F; Fremeaux-Bacchi V; Józsi M; Kavanagh D; Lambris JD; Noris M; Pickering MC; Remuzzi G; de Córdoba SR; Sethi S; Van der Vlag J; Zipfel PF; Nester CM
Nat Rev Nephrol; 2019 Mar; 15(3):129-143. PubMed ID: 30692664
[TBL] [Abstract][Full Text] [Related]
42. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
43. Dense Deposit Disease Mimicking a Renal Small Vessel Vasculitis.
Singh L; Singh G; Bhardwaj S; Sinha A; Bagga A; Dinda A
J Am Soc Nephrol; 2016 Jan; 27(1):59-62. PubMed ID: 26361799
[TBL] [Abstract][Full Text] [Related]
44. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation.
Zand L; Lorenz EC; Cosio FG; Fervenza FC; Nasr SH; Gandhi MJ; Smith RJ; Sethi S
J Am Soc Nephrol; 2014 May; 25(5):1110-7. PubMed ID: 24357668
[TBL] [Abstract][Full Text] [Related]
45. Utility of immunohistochemistry with C3d in C3 glomerulopathy.
Snijders MLH; van de Wall-Neecke BJ; Hesselink DA; Becker JU; Clahsen-van Groningen MC
Mod Pathol; 2020 Mar; 33(3):431-439. PubMed ID: 31477814
[TBL] [Abstract][Full Text] [Related]
46. Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.
Rudnicki M
Biomed Res Int; 2017; 2017():2180508. PubMed ID: 28573137
[TBL] [Abstract][Full Text] [Related]
47. Dense deposit disease in a child with febrile sore throat.
Conti G; De Vivo D; Vitale A; Fede C; Santoro D
Saudi J Kidney Dis Transpl; 2017; 28(4):925-928. PubMed ID: 28748900
[TBL] [Abstract][Full Text] [Related]
48. C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis.
Ponticelli C; Calatroni M; Moroni G
Front Med (Lausanne); 2023; 10():1289812. PubMed ID: 38076230
[TBL] [Abstract][Full Text] [Related]
49. Crescentic glomerulonephritis developing in the course of idiopathic membranoproliferative glomerulonephritis.
Sharma A; Gupta R; Lal C; Agarwal SK; Dinda AK
Saudi J Kidney Dis Transpl; 2013 Mar; 24(2):333-7. PubMed ID: 23538361
[TBL] [Abstract][Full Text] [Related]
50. Toward a working definition of C3 glomerulopathy by immunofluorescence.
Hou J; Markowitz GS; Bomback AS; Appel GB; Herlitz LC; Barry Stokes M; D'Agati VD
Kidney Int; 2014 Feb; 85(2):450-6. PubMed ID: 24067430
[TBL] [Abstract][Full Text] [Related]
51. C4d as a Diagnostic Tool in Proliferative GN.
Sethi S; Nasr SH; De Vriese AS; Fervenza FC
J Am Soc Nephrol; 2015 Nov; 26(11):2852-9. PubMed ID: 25991041
[TBL] [Abstract][Full Text] [Related]
52. Treatment of C3 glomerulopathy with complement blockers.
Vivarelli M; Emma F
Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307
[TBL] [Abstract][Full Text] [Related]
53. Streptococcal infection as possible trigger for dense deposit disease (C3 glomerulopathy).
Prasto J; Kaplan BS; Russo P; Chan E; Smith RJ; Meyers KE
Eur J Pediatr; 2014 Jun; 173(6):767-72. PubMed ID: 24384791
[TBL] [Abstract][Full Text] [Related]
54. C3 glomerulopathy in children: Is there still a place for anti-cellular immunosuppression?
Kojc N; Bahovec A; Levart TK
Nephrology (Carlton); 2019 Feb; 24(2):188-194. PubMed ID: 30393898
[TBL] [Abstract][Full Text] [Related]
55. Pediatric C3 glomerulopathy: a 12-year single-center experience.
Zahir Z; Wani AS; Gupta A; Agrawal V
Pediatr Nephrol; 2021 Mar; 36(3):601-610. PubMed ID: 33000324
[TBL] [Abstract][Full Text] [Related]
56. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
Garg N; Zhang Y; Nicholson-Weller A; Khankin EV; Borsa NG; Meyer NC; McDermott S; Stillman IE; Rennke HG; Smith RJ; Pavlakis M
Nephrol Dial Transplant; 2018 Dec; 33(12):2260-2265. PubMed ID: 29370420
[TBL] [Abstract][Full Text] [Related]
57. Rituximab fails where eculizumab restores renal function in C3nef-related DDD.
Rousset-Rouvière C; Cailliez M; Garaix F; Bruno D; Laurent D; Tsimaratos M
Pediatr Nephrol; 2014 Jun; 29(6):1107-11. PubMed ID: 24408225
[TBL] [Abstract][Full Text] [Related]
58. Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.
Ueda C; Horinouchi T; Inoki Y; Ichikawa Y; Tanaka Y; Kitakado H; Kondo A; Sakakibara N; Nagano C; Yamamura T; Fujimura J; Kamiyoshi N; Ishimori S; Ninchoji T; Kaito H; Shima Y; Iijima K; Nozu K; Yoshikawa N
Pediatr Nephrol; 2024 Apr; ():. PubMed ID: 38662234
[TBL] [Abstract][Full Text] [Related]
59. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.
Ozkaya O; Nalcacioglu H; Tekcan D; Genc G; Meydan BC; Ozdemir BH; Baysal MK; Keceligil HT
Pediatr Nephrol; 2014 Jul; 29(7):1283-7. PubMed ID: 24464478
[TBL] [Abstract][Full Text] [Related]
60. Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy.
Kerns E; Rozansky D; Troxell ML
Pediatr Nephrol; 2013 Nov; 28(11):2227-31. PubMed ID: 23892798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
